Abstract:Although the microbiota has been extensively associated with HIV pathogenesis, the majority of studies, particularly those using omics techniques, are largely correlative and serve primarily as a basis for hypothesis generation. Furthermore, most have focused on characterizing the taxonomic composition of the bacterial component, often overlooking other levels of the microbiome. The intricate mechanisms by which the microbiota influences immune responses to HIV are still poorly understood. Interventional studies on gut microbiota provide a powerful tool to test the hypothesis of whether we can harness the microbiota to improve health outcomes in people with HIV.

What problem does this paper attempt to address?

The paper attempts to address the multifaceted roles of the gut microbiome in HIV/SIV disease progression and its potential as a therapeutic target. Specifically, the paper focuses on the following aspects: 1. **Relationship between the microbiome and HIV/SIV disease**: The paper reviews the complex roles of the gut microbiome during HIV/SIV infection, particularly how it influences immune responses and disease progression. 2. **Microbiome imbalance and systemic inflammation**: The paper explores the relationship between gut microbiome imbalance (i.e., dysbiosis) and systemic inflammation, highlighting that microbiome-based therapies may open new avenues for HIV management. 3. **Therapeutic interventions**: The paper discusses in detail the effectiveness of various interventions, including probiotics, prebiotics, fecal microbiota transplantation, and targeted dietary adjustments, aimed at reducing inflammation caused by microbiome imbalance. 4. **Research challenges**: The paper also points out the challenges in this research field, such as the difficulty in inducing long-term microbiome changes, the complexity of research design, and the obstacles in translating research findings into clinical practice. 5. **Future directions**: Finally, the paper looks ahead to future research directions, emphasizing the need for a more detailed understanding of the interactions between the microbiome and the immune system, the development of personalized microbiome therapies, and the application of new technologies to identify potential therapeutics. In summary, the paper aims to explore the potential and challenges of the gut microbiome in HIV/SIV treatment through a comprehensive analysis of existing research, providing a theoretical foundation and practical guidance for future therapeutic strategies.

From dysbiosis to defense: harnessing the gut microbiome in HIV/SIV therapy